Treatment for Chronic Dry Eye Syndrome
Treatment for Chronic Dry Eye Syndrome
Aqueous formulation of artificial tears based on the natural lipids of the meibomian secretions: Meibomian secretions are composed of a heterogenous lipid mixture, which forms a protective lipid surface that maintains the integrity of the tear film. This invention provides an aqueous formulation of artificial tears based on the natural lipids of the meibomian secretions.
New York, NY, United States
Overview Comments Tagged publications (1)

Background

Artificial tears based on the that mimic natural lipids produced by tear ducts: Chronic dry eye syndrome (CDES) is one of the most common ocular problems. Although a number of etiologies result in CDES, the condition arises from a disruption of the pre-ocular tear film leading to either reduced tear production or excess tear evaporation. The human tear film is essential for normal eye function. Mild deficiencies of tears produce a subjective foreign body or gritty sensation, while more severe deficiencies can lead to epithelial defects, corneal dryness, and vision loss. While the most common cause of tear deficiencies are autoimmune diseases, the majority of patients with CDES due to excess tear evaporation suffer from meibomian gland dysfunction resulting in lipid tear deficiency. The meibomian glands in the eyelids produce the oily lipid layer that reduces evaporation of tears. Currently treatment options include many commercially available over-the-counter artificial tear formulations and one pharmacological agent aimed at immune associated CDES. Although, a number of products are in developments there is a clear need for artificial tears that mimic essential properties of human tears.

Aqueous formulation of artificial tears based on the natural lipids of the meibomian secretions: Meibomian secretions are composed of a heterogenous lipid mixture, which forms a protective lipid surface that maintains the integrity of the tear film. This invention provides an aqueous formulation of artificial tears based on the natural lipids of the meibomian secretions. The inventors have identified at the molecular level the genes and corresponding enzymes that produce the lipid components of human tears. In addition, they have developed an expression system and purification protocol of these lipids. Furthermore, the potential exists to precisely control the physiological properties of these lipids.

Market Overview: As one of the most common ocular problems there is a clear market opportunity for this technology. In the United States alone, 5.5 million individuals suffer from some form of chronic dry eye. In addition, with only one product currently on the market there is significant potential for other treatment options. Thus, the market is still in its infancy with substantial growth opportunity. Frost and Sullivan estimate that although the market was nearly $200 million in 2005 they forecast a $1.5 billion market by 2012.

Lead Inventors: Stephen L. Sturley, Ph.D. and Stephen Trokel, M.D.

Similar innovations

Back
or
Back
Back
or
Back
  • Gene therapy for inflammatory and autoimmune diseases
  • This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressants.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Parkinson's and Huntington's Treatment
  • This technology is an antisense oligonucleotide to the protein Nedd2. Nedd2 is an aspartase expressed by neuronal cells and plays a crucial role in apoptosis. When neurons are deprived of cytokines such as nerve growth factor (NGF), Nedd2 expression is upregulated as part of the apoptotic pathway. This technology is an antisense oligonucleotide (ANedd) capable of blocking expression of Nedd2, thereby inhibiting apoptosis.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Binding Partner to Tumor Suppressor
  • HAUSP (herpesvirus-associated ubiquitin-specific protease) as a novel p53-interacting deubiquitinase. HAUSP strongly stabilizes p53 by deubiquitinating p53, even in the presence of excess Mdm2. In addition, HAUSP binds directly to Mdm2 in such a way as to form a three-protein complex with p53 and, via this indirect interaction, p53 is also stabilized. The technology provides methods for screening HAUSP-p53 and HAUSP-Mdm2 interactions.
  • Read more
  • TherapeuticsMethods
  • New York, NY, United States
  • Stanford University
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 159

Send Us a Message